

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine

Appendix

Appendix Table 1. The median (and IQR) values of the antibody levels in response to CoronaVac and BNT162b2 vaccines

Timepoint, no. participants	Median AU/mL (IQR)	
	S IgG antibodies	N IgG antibodies
P1, n = 99	3.0 (0.9–74.70)	0.03 (0.02–0.16)
P2, n = 99	188.0 (75–806.5)	0.14 (0.05–1.05)
P3, n = 95	1,081 (665–1,811)	1.58 (0.55–3.01)
P4, n = 94	477.7 (256.8–880.2)	0.76 (0.24–1.63)
P5, n = 89	282.3 (103.1–500.5)	0.27 (0.10–0.90)
P6, n = 84	200.2 (84.18–585.7)	0.13 (0.07–0.61)
P7, n = 74	41,371 (29,233–73,465)	0.18 (0.08–0.68)

Appendix Table 2. The median (and IQR) values of the antibody levels in response to CoronaVac and BNT162b2 vaccines in COVID-19 positive and negative persons

Timepoint, no. participants	COVID-19 negative		COVID-19 positive	
	S IgG antibodies	N IgG antibodies	S IgG antibodies	N IgG antibodies
P1, n = 99	1.35 (0.55–3.83)	0.03 (0.02–0.04)	270.2 (173.5–548.2)	0.32 (0.18–1.91)
P2, n = 99	124.1 (52.98–242)	0.09 (0.04–0.32)	1,245 (725.3–2,296)	1.51 (0.78–3.82)
P3, n = 95	1,035 (563–1,628)	0.99 (0.51–2.83)	1,323 (875–2,263)	2.17 (1.32–4.08)
P4, n = 94	399 (231.2–777.5)	0.36 (0.19–1.11)	845.8 (509.2–1,462)	1.55 (0.80–3.11)
P5, n = 89	172.9 (80.53–349)	0.16 (0.09–0.65)	546.4 (356.6–724.9)	0.91 (0.37–1.69)
P6, n = 84	133.5 (64.83–289.4)	0.11 (0.06–0.25)	627.4 (342.6–1,098)	0.66 (0.25–1.40)
P7, n = 74	52,372 (37,075–81,365)	0.11 (0.06–0.41)	30,067 (22,276–40,679)	0.51 (0.23–1.54)